Abstract 905: Associations with Breast Cancer Survival Replicated for Three SNPs: A Report from the Shanghai Breast Cancer Survival Study and Shanghai Breast Cancer Study

Alicia C. Beeghly-Fadiel,Jirong Long,Yutang Gao,Ying Zheng,Qiuyin Cai,Kai Gu,Zhi Chen,Wei Lu,Wei Zheng,Xiao Ou Shu

DOI: https://doi.org/10.1158/1538-7445.am10-905

IF: 11.2

2010-01-01

Cancer Research

Abstract:We have previously reported associations between nine single nucleotide polymorphisms (SNPs) and breast cancer outcomes from the Shanghai Breast Cancer Study (SBCS, Stage I). We evaluated these SNPs in association with overall survival (OS) and disease free-survival (DFS) among participants of the Shanghai Breast Cancer Survival Study (SBCSS) and participants of the second phase of SBCS (Stage 2). The mean follow-up time of the 1,115 Stage 1 participants was 6.5 years; the mean follow-up time of the 5,381 Stage 2 participants was 4.2 years. Models of effect and subgroup analyses were conducted based on published results from Stage 1. A missense SNP in exon 1 of TGFβ1 (rs1800470) was associated with improved overall survival in a recessive fashion (p-value = 0.028). Minor allele homozygotes (TT) fared slightly better than major allele carriers (CT and CC) (OS hazard ratio (HR): 0.8, 95% confidence interval (CI): 0.6-1.0); this effect was slightly attenuated after adjustment for known prognostic factors including age, disease stage, tumor estrogen and progesterone receptor status, and disease treatment (p-value = 0.052). A SNP downstream of the MMP7 gene (rs11225297), in high linkage disequilibrium with a nearby functional SNP, was associated with improved overall survival in an additive manner (p-value = 0.013). Compared to major allele homozygotes (AA), heterozygotes (AT) fared moderately better (OS HR: 0.8, 95% CI: 0.7-1.0), while homozygotes (TT) fared much better (OS HR: 0.5, 95% CI: 0.3-1.0); this affect was strengthened by adjusting for known covariates (p-value = 0.002). Finally, a functional promoter SNP in MMP8 (rs11225395) was found to be associated with better prognosis among early stage patients (TNM less than 3) in a dominant manner (p-value = 0.007). Early stage minor allele carriers (CT and TT) had better survival (DFS and OS HRs: 0.7, 95% CI: 0.5-0.9); these effects were unaltered by adjusting for covariates (p-values = 0.012). In summary, we were able to replicate associations with breast cancer survival for three of nine previously reported SNPs. These findings suggest that genetic polymorphism in genes governing the tumor microenvironment may play an important role in breast cancer prognosis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 905.